Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Interaction of the Sulfonylthiourea HMR 1833 with Sulfonylurea Receptors and Recombinant ATP-Sensitive K+ Channels: Comparison with Glibenclamide

Ulrich Russ, Ulf Lange, Cornelia Löffler-Walz, Annette Hambrock and Ulrich Quast
Journal of Pharmacology and Experimental Therapeutics December 2001, 299 (3) 1049-1055;
Ulrich Russ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulf Lange
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cornelia Löffler-Walz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annette Hambrock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Quast
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

This article has a correction. Please see:

  • Correction to “Interaction of the Sulfonylthiourea HMR 1833 with Sulfonylurea Receptors and Recombinant ATP-Sensitive K+ Channels: Comparison with Glibenclamide” - March 01, 2002

Abstract

The novel sulfonylthiourea 1-[[5-[2-(5-chloro-o-anisamido)ethyl]-2-methoxyphenyl]sulfonyl]-3-methylthiourea (HMR 1883), a blocker of ATP-sensitive K+channels (KATP channels), has potential against ischemia-induced arrhythmias. Here, the interaction of HMR 1883 with sulfonylurea receptor (SUR) subtypes and recombinant KATPchannels is compared with that of the standard sulfonylurea, glibenclamide, in radioligand receptor binding and electrophysiological experiments. HMR 1883 and glibenclamide inhibited [3H]glibenclamide binding to SUR1 withKi values of 63 μM and 1.5 nM, and [3H]opener binding to SUR2A/2B withKi values of 14/44 μM and 0.5/2.8 μM, respectively (values at 1 mM MgATP). The interaction of HMR 1883 with the SUR2 subtypes was more sensitive to inhibition by MgATP and MgADP than that of glibenclamide. In inside-out patches and in the absence of nucleotides, HMR 1883 inhibited the recombinant KATPchannels from heart (Kir6.2/SUR2A) and nonvascular smooth muscle (Kir6.2/SUR2B) with IC50 values of 0.38 and 1.2 μM, respectively; glibenclamide did not discriminate between these channels (IC50 ∼ 0.026 μM). In whole cells, the recombinant vascular KATP channel, Kir6.1/SUR2B, was inhibited by HMR 1883 and glibenclamide with IC50 values of 5.3 and 0.043 μM, respectively. The data show that the sulfonylthiourea exhibits a selectivity profile quite different from that of glibenclamide with a major loss of affinity toward SUR1 and slight preference for SUR2A. The stronger inhibition by nucleotides of HMR 1883 binding to SUR2 (as compared with glibenclamide) makes the sulfonylthiourea an interesting tool for further investigation.

Footnotes

  • Supported by Deutsche Forschungsgemeinschaft Grant Qu 100/2-4 (to A.H. and U.Q.), by the Fortüne program of the Medical Faculty of the University of Tübingen (to U.L.), and by the Dr. Karl-Kuhn Foundation.

  • Abbreviations:
    HMR 1883
    1-[[5-[2-(5-chloro-o-anisamido)ethyl]-2-methoxyphenyl]sulfonyl]-3-methylthiourea
    KATP channel
    ATP-sensitive K+ channel
    Kir
    inwardly rectifying K+ channel
    SUR
    sulfonylurea receptor
    • Received June 14, 2001.
    • Accepted August 10, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 299 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 299, Issue 3
1 Dec 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Interaction of the Sulfonylthiourea HMR 1833 with Sulfonylurea Receptors and Recombinant ATP-Sensitive K+ Channels: Comparison with Glibenclamide
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Interaction of the Sulfonylthiourea HMR 1833 with Sulfonylurea Receptors and Recombinant ATP-Sensitive K+ Channels: Comparison with Glibenclamide

Ulrich Russ, Ulf Lange, Cornelia Löffler-Walz, Annette Hambrock and Ulrich Quast
Journal of Pharmacology and Experimental Therapeutics December 1, 2001, 299 (3) 1049-1055;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleCARDIOVASCULAR

Interaction of the Sulfonylthiourea HMR 1833 with Sulfonylurea Receptors and Recombinant ATP-Sensitive K+ Channels: Comparison with Glibenclamide

Ulrich Russ, Ulf Lange, Cornelia Löffler-Walz, Annette Hambrock and Ulrich Quast
Journal of Pharmacology and Experimental Therapeutics December 1, 2001, 299 (3) 1049-1055;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Effects of Four COVID-19 Drugs on hERG Channels
  • Anti-apoptotic effect of rosuvastatin via autophagy
  • Improved Assessment of Cardiovascular Safety Data
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics